Kei Takamura
Kei Takamura publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, on topics such as Lung Cancer Treatments and Mutations, Lung Cancer Research Studies and Lung Cancer Diagnosis and Treatment.
- World rank
- #4,592,925 of 7,710,434 ranked researchers
- Rank in Japan
- #135,520 of 383,136
- Works
- 126
- Citations
- 1.3k
- Citations per work
- 10.2
What does Kei Takamura research?
Kei Takamura's work is mostly in Medicine (68%), Biochemistry, Genetics and Molecular Biology (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences8668.2%
- Medicine8668.2%
- Everything else3427.1%
- Life Sciences64.7%
- 1Pulmonary and Respiratory Medicine37% of their works
- 2Oncology23% of their works
- 3Molecular Biology5% of their works
- 4Epidemiology4% of their works
- 5Surgery3% of their works
- 6Radiology, Nuclear Medicine and Imaging2% of their works
Research topics
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Glycosylation and Glycoproteins Research
Which keywords describe Kei Takamura's research?
The keywords of their largest research topics: Clinical Trials, Targeted Therapy, Chemotherapy, ALK Inhibitors, EGFR Mutations, Genomic Profiles, Small-Cell Lung Cancer and CT Screening.
- Glycosylation
- KRAS Mutations
- Fibroblast Activation Protein
- Idiopathic Pulmonary Fibrosis
- PD-1 and PD-L1
- Tumor Microenvironment
- CT Screening
- Genomic Profiles
- ALK Inhibitors
- Targeted Therapy
- Clinical Trials
- Chemotherapy
- EGFR Mutations
- Small-Cell Lung Cancer
- Lung Cancer
- Immune Checkpoint Blockade
- Fibrosis
- Cetuximab
- Immunosuppression
- Glycans
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Clinical Trials782 topics
- Targeted Therapy782 topics
- Chemotherapy633 topics
- ALK Inhibitors441 topic
- EGFR Mutations441 topic
- Genomic Profiles341 topic
- Small-Cell Lung Cancer341 topic
- CT Screening231 topic
- Lung Cancer231 topic
- Tumor Microenvironment182 topics
- Immune Checkpoint Blockade121 topic
- PD-1 and PD-L1121 topic
- Fibrosis81 topic
- Idiopathic Pulmonary Fibrosis81 topic
- Cetuximab61 topic
- Fibroblast Activation Protein61 topic
- Immunosuppression61 topic
- KRAS Mutations61 topic
- Glycans41 topic
- Glycosylation41 topic
Where does Kei Takamura work?
Kei Takamura's main affiliation in the publication record is Obihiro Kosei General Hospital, Japan.
How many publications and citations does Kei Takamura have?
OpenAlex counts 126 works and 1,289 citations for Kei Takamura, an h-index of 16, ranking #4,592,925 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Kei Takamura. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.